Trial record 1 of 1 for:
MOR208C115
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05222555 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 3, 2022
Last Update Posted : May 14, 2024
|
Sponsor:
MorphoSys AG
Information provided by (Responsible Party):
MorphoSys AG
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | November 30, 2024 |
| Estimated Study Completion Date : | October 31, 2027 |